Navigation Links
Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Date:9/17/2007

NEW YORK, Sept. 17 /PRNewswire/ -- ExL Pharma is pleased to announce three Clinical Data Focused conferences which cover many of the leading issues that are impacting the pharmaceutical industry today. These events offer educational and networking opportunities for Clinical, R&D, Regulatory and Medical Affairs executives from large to small pharmaceutical, biotech, device and medical technology companies.

Listed below are details on some of the featured events and highlights from those conferences:

October 15-16, San Francisco, CA

2nd Data Monitoring Committees/DSMBs Conference -- Evaluating Trial Safety

and Efficacy through Independent Examination of Interim Clinical Data

Following a successful inaugural DMC conference in February of 2007, where over 100 industry experts gathered in Philly, ExL Pharma is proud to announce the 2nd DMC conference taking place October 15-16 in San Francisco where the industry will once again gather to evaluate trial safety and efficacy through independent examination of interim clinical data. Hear case study examples from GSK, AstraZeneca, Genentech, Amgen and join the industry's leading authorities on Drug Safety, Regulatory Affairs and Biostatistics to discuss experiences, strategies and best practices for working with DMCs and incorporating them into clinical trial designs to mitigate risk, optimize resource allocation, reassure study integrity and increase safety.

November 5-6, Arlington, VA

Pediatric Clinical Trials Conference -- Increasing Efficiency in Drug

Development by Redefining Global Regulation and Identifying Trial

Enhancements

Featuring roundtable discussions chaired by Dean Steven Spielberg from Dartmouth Medical School; topics lead by experts in each field include CNS/Psychiatry, Infectious Disease, Oncology, Gastroenterology, and Geographic Study Differences. Other event presentations include NICHD perspective on Best Pharmaceuticals for Children Act, changes in pediatric regulatory landscape, and industry sponsored research.

December 3-4 2007, Philadelphia, PA

Pharmacovigilance Summit 2007 -- Developing and Implementing Compliant

Strategies to Minimize the Risk of Adverse Drug Reactions and Increase

Drug Safety

The only conference focusing on developing and implementing compliant strategies to minimize the risk of adverse drug reactions and increase drug safety. AstraZeneca, Cephalon Inc, Intermune, Sunesis Pharmaceuticals and more discuss practical crisis management and communications strategies, measuring the effectiveness of your pharmacovigilance efforts, and evaluating the effectiveness of your risk management plans and tools and more. Pre-conference workshop on The Impact of Regulation on Drug Safety.

To view our full list of upcoming conferences and webinars and details on our expert speaking faculties or to REGISTER, Log onto: http://www.exlpharma.com.

*Please mention Registration Code: ECL913 when registering

About ExL

ExL Pharma, a division of ExL Events, Inc., is an emerging leader in developing innovative, educational events that serve the healthcare community and allied professionals. Behind our diverse conference portfolio, our experienced team conducts extensive market research and targeted outreach. The results translate into innovative, high-quality conference events designed to exceed the dynamic informational needs of the healthcare community.


'/>"/>
SOURCE ExL Pharma
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Pharma majors gear to supply anti-anthrax drug
2. First Artificial Heart patient has Major setback
3. Allergies: A major health problem
4. Animal insulin product to be discontinued by drug major Eli Lilly
5. Vision Loss Due To Diabetic Retinopathy a Major Cause Of Concern
6. Depression Found To Be A Major Cause for Death in Elderly
7. Genetics Has A Major Role To Play In Body Shape.
8. “Yes, I need Cosmetic surgery” – view of majority wome
9. Pigs Population A Major Threat To Encephalitis Ravaged UP
10. Unsafe Injections and Unclean Hand hygiene major cause of hospital infections in India
11. Delhi Government To Interlink All Major Hospitals Through e-Governance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Somnoware, a leading ... Word(TM) Online(TM), which enables sleep physicians to create and edit their interpretation reports. ... and provides a familiar interface that does not require additional training to use. ...
(Date:4/28/2017)... Grants Pass, OR (PRWEB) , ... April 28, ... ... Adetutu Ijose, http://www.foodsthathealdaily.com , http://www.wiredlifesolutions.com , “Computers are everywhere and ... Kleyne Hour Power of Water, Global Climate Change and Your Health on Voice ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood ... to the labor and delivery team at Women’s Hospital at Renaissance in Edinburg for ... birth at the hospital and decide to donate. , “Women’s Hospital at Renaissance ...
(Date:4/28/2017)... ... ... Pastor and Overseer at The House of Yahweh in Abilene, Texas, has published a new ... not. Yisrayl says with so many titles and names for the Creator, it’s hard ... a little Scripture, backed with a lot of research, the truth is undeniable. , ...
(Date:4/28/2017)... , ... April 28, 2017 , ... NuevaCare, a leading ... diverse as Millbrae, Burlingame, and Palo Alto, is proud to announce information upgrades to ... to bookmark and read organized content on topics such as home care (generally) as ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
Breaking Medicine Technology: